Clinical Trials Browser

NSCLC × pembrolizumab × 1 year × Clear all

NCT04557007 2026-01-29

Oncomabs

NSCLC

NCT05078931 2025-07-30

A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients

Phase 2 Active not recruiting

NSCLC